291289-66-2

Upstream product

• 53663-39-1 3-methyl-2-bromobenzoic acid 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 

Downstream Products

• 291289-38-8 benzyl-2-vinyl-3-methylbenzoate 
• 291289-36-6 benzyl-3-methyl-2-phenylbenzoate 
• 1048367-60-7 benzyl 4'-tert-butyl-6-methylbiphenyl-2-carboxylate 
• 1374020-59-3 C₁₄H₁₂O₄ 
• 1374020-65-1 C₁₅H₁₄O₅ 
• 1374020-58-2 C₂₈H₂₄O₄ 
• 1374020-64-0 C₂₉H₂₆O₅ 
• 916904-35-3 2-benzyl 2'-methyl 6-methylbiphenyl-2,2'-dicarboxylate 
• 916904-30-8 benzyl 2'-formyl-6-methylbiphenyl-2-carboxylate 

Relevant academic research and scientific papers

Psoromic acid is a selective and covalent rab-prenylation inhibitor targeting autoinhibited rabggtase

Post-translational attachment of geranylgeranyl isoprenoids to Rab GTPases, the key organizers of intracellular vesicular transport, is essential for their function. Rab geranylgeranyl transferase (RabGGTase) is responsible for prenylation of Rab proteins

GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS

Compounds represented by formula (I): are inhibitors of gut microsomal triglyceride transfer protein. Such compounds are useful in treating diseases or conditions such as diabetes and obesity, along with patients are risk for developing such diseases or conditions.

Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand

Inhibition of tissue factor/factor VIIa complex (TF/FVIIa) is an attractive strategy for antithrombotic therapies. We began with an investigation of a non-amidine TF/FVIIa inhibitor based on a modification of amidine compound 1. Optimization of the substituents on the P1 phenyl portion of the compound 1 led to a neutral or less basic alternative for the 4-amidinophenyl moiety. By further optimization of the substituents on the central phenyl ring, a highly potent and selective TF/FVIIa inhibitor 17d was discovered.

3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity

The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4fare defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.